Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PMV Pharmaceuticals Inc PMVP

Healthcare Biotechnology
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally... see more

Recent & Breaking News (NDAQ:PMVP)

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

GlobeNewswire June 9, 2021

PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference

GlobeNewswire June 3, 2021

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

GlobeNewswire May 14, 2021

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

GlobeNewswire May 5, 2021

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

GlobeNewswire April 10, 2021

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

GlobeNewswire April 6, 2021

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

GlobeNewswire March 10, 2021

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

GlobeNewswire March 3, 2021

PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference

GlobeNewswire February 23, 2021

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

GlobeNewswire February 16, 2021

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

GlobeNewswire November 24, 2020

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

GlobeNewswire November 23, 2020

PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

GlobeNewswire November 13, 2020

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

GlobeNewswire October 13, 2020

PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

GlobeNewswire September 29, 2020